Zymeworks Q1 revenue $27.1M, net loss narrows to $22.6M; cash runway into 2H-2027

Zymeworks Inc.

2025-Q1 EPS reported -$0.30 revenue$27,110,000

Revenue of $27.1M (vs. $10.0M in Q1 2024); net loss of $22.6M improved from $31.7M.
Cash resources $321.6M; combined with anticipated milestones expected to fund operations into 2H-2027.
Partner Jazz received EMA positive opinion for zanidatamab in HER2+ BTC; final decision pending.
Recognized $14.0M GSK milestone (paid Apr 2025) and $3.1M Daiichi Sankyo milestone; additional milestones remain.
Appointed Dr. Sabeen Mekan as SVP Clinical Development; six preclinical posters presented at AACR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.